Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.28 USD | +0.34% | +0.71% | -16.73% |
Financials (USD)
Sales 2024 * | 132M | Sales 2025 * | 210M | Capitalization | 2.33B |
---|---|---|---|---|---|
Net income 2024 * | -280M | Net income 2025 * | -133M | EV / Sales 2024 * | 14.6 x |
Net cash position 2024 * | 416M | Net cash position 2025 * | 288M | EV / Sales 2025 * | 9.76 x |
P/E ratio 2024 * |
-9.19
x | P/E ratio 2025 * |
-19.1
x | Employees | 226 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.1% |
Latest transcript on Rhythm Pharmaceuticals, Inc.
1 day | +0.34% | ||
1 week | +0.71% | ||
Current month | -11.65% | ||
1 month | -11.65% | ||
3 months | -13.69% | ||
6 months | +74.00% | ||
Current year | -16.73% |
Managers | Title | Age | Since |
---|---|---|---|
David Meeker
CEO | Chief Executive Officer | 69 | 15-10-31 |
Hunter Smith
DFI | Director of Finance/CFO | 56 | 17-06-30 |
Joseph Shulman
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christophe Jean
BRD | Director/Board Member | 67 | 15-03-31 |
Jennifer Good
BRD | Director/Board Member | 59 | 19-06-18 |
David McGirr
BRD | Director/Board Member | 69 | 15-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.14% | 0 M€ | 0.00% | - | |
0.11% | 0 M€ | 0.00% | - | |
0.09% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 38.28 | +0.34% | 305,047 |
24-04-25 | 38.15 | -3.93% | 424,460 |
24-04-24 | 39.71 | -0.72% | 398,307 |
24-04-23 | 40 | +2.54% | 413,704 |
24-04-22 | 39.01 | +2.63% | 390,372 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.73% | 2.33B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RYTM Stock